Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of Common Stock in open-market transactions. The sales occurred on April 1, 2026 at prices ranging from about $771.32 to $779.71, executed in multiple small tranches using volume-weighted average prices.
The filing states these dispositions were made under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Following the transactions, Ryan directly holds 17,603 Common Stock shares of Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc — Amendment No. 7 to a Schedule 13G/A filed by The Vanguard Group reports 0 shares beneficially owned and 0% of the common stock. The filing states Vanguard completed an internal realignment on January 12, 2026, and certain subsidiaries will report disaggregated holdings under SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It notes Vanguard and related investment vehicles retain the right to dividends or proceeds where applicable but that no single external person holds more than 5% of the class in the reported holdings.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of common stock in a series of open-market transactions on March 2, 2026 under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. The shares were sold at volume-weighted average prices ranging from $777.08 to $789.37 per share. After these sales, Ryan directly owned 17,703 Regeneron shares.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported option exercises and related share sales. On February 19, 2026, Zoghbi exercised a non-qualified stock option for 1,638 shares at an exercise price of $0.00, receiving 1,638 shares of common stock at $376.69 per share.
The same day, Zoghbi executed multiple open-market sales totaling 1,638 common shares at prices generally in the high-$770s to around $790 per share, pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025. After these transactions, Zoghbi held 1,703 Regeneron common shares directly.
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 4,272 shares.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades. Reported sale prices ranged from about $775.63 to $787.82 per share.
The filing states these transactions were made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025, which pre-schedules trades. Following the transactions, Ryan directly beneficially owned 17,803 shares of Regeneron common stock.
A person associated with the issuer has filed a Form 144 to potentially sell 400 shares of common stock through J.P. Morgan Securities LLC on or about 02/09/2026 on NASDAQ. The filing lists an aggregate market value of 314204 for these shares and notes that 103902660 shares of this class were outstanding. The 400 shares were originally acquired on 08/22/2013 from the issuer as compensation.
Regeneron Pharmaceuticals security holder plans to sell 2,036 common shares under Rule 144. The planned sale is through UBS Financial Services on NASDAQ, with an aggregate market value of 1,594,534.12 and 103,902,660 common shares stated as outstanding.
The shares to be sold were acquired from the issuer via two transactions: 1,000 shares through a cash exercise of stock options dated 02/09/2026, and 1,036 shares through a restricted stock award dated 12/08/2025.
Regeneron Pharmaceuticals, Inc. filed a Form 13F holdings report disclosing 2 holdings with an aggregate reported market value of $33,799,428. The report is signed by Leonard Brooks, Senior Vice President, Treasurer, and dated 02-06-2026. The filing lists the manager's address as 777 Old Saw Mill River Road, Tarrytown, NY.